If your genes could set an alarm clock, EZH1 might be the one ringing the bell. A new study has revealed how this ...

DURHAM, N.C.and SEATTLE, Jan. 28, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at ...

Salk scientists identify protein BCL6 as a key regulator of muscle maintenance in mice; BCL6-enhancing therapies may prevent ...

DURHAM, N.C. - Humacyte, Inc. (NASDAQ:HUMA), a biotechnology firm specializing in bioengineered human tissues with a current market capitalization of $580 million, and Pluristyx, Inc., a provider of ...

Symptoms of Huntington's disease appear late in life. Research reveals how DNA repeats grow toxic over time, explaining the ...

Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue ...

Salk Institute researchers have identified a key protein that may help users of GLP-1 drugs such as Ozempic and Wegovy ...

Learn about Jennifer Lewis, Harvard Professor and recipient of the 2025 James Prize. Explore her groundbreaking research in ...

The recent surge in popularity of weight loss drugs like Ozempic, collectively called GLP-1s, has sparked renewed scientific ...

Roche announces positive results from EMBARK phase III study of Elevidys in ambulatory individuals with DMD: Basel Tuesday, January 28, 2025, 11:00 Hrs [IST] Roche announced posit ...

By using genetic material from two male mice, researchers successfully created pups that survived to adulthood, offering ...